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Abstract
The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)
study is a multinational, double-blind, randomized, placebo controlled trial which was recently
published. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in
patients with diabetic nephropathy. The primary efficacy measure was the time to the first event
of the composite end point of a doubling of serum creatinine, end-stage renal disease, or death.
The conclusion was that losartan led to significant improvement in renal outcomes, that was
beyond that attributable to blood pressure control in patients with type 2 diabetes and
nephropathy.
The perusal of the report raises concern, regarding to both the patient population as well as the
outcome measures. At randomization, the placebo group included more patients with angina,
myocardial infarction and lipid disorders than the losartan group. Information on glucose
metabolism was disregarded, and data on antihyperglycemic therapy – which may have undesirable
influences on cardiac performance – were not included in a multivariate analysis. In addition, only
data on first hospitalization were reported, whilst information on total specific-cause
hospitalizations was disregarded, thus potentially masking further unfavorable events. Furthermore,
creatinine seems not to be a reliable surrogate end point. Based on its mechanism of action,
losartan may possess favorable renoprotective properties. However, due to the methodological
flaws and the incomplete data in the RENAAL study, the question of the effectiveness and safety of
this drug in diabetic nephropathy remains yet unanswered.
The RENAAL (Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan) study is a multi-
national, double-blind, randomized, placebo controlled
trial which was recently published [1]. The study aimed to
evaluate the effect of the angiotensin receptor blocker
losartan – alone or in combination with other antihyper-
tensive drugs (excluding angiotensin-converting enzyme
inhibitors) – in patients with diabetic nephropathy. The
primary efficacy measure was the time to the first event of
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the composite end point of a doubling of serum creati-
nine, end-stage renal disease, or death. The conclusion of
the study was that losartan led to significant improvement
in renal outcomes, that was beyond that attributable to
blood pressure control in patients with type 2 diabetes
and nephropathy.
Three main factors can be identified in the framework of
a clinical trial: the therapeutic intervention, the patient
population and the outcome measures by which the dif-
ferent therapy groups will be compared [2]. In the present
case, the results of the trial depend on the interplay be-
tween the therapeutic intervention in the RENAAL study,
i.e. losartan 50 or 100 mg daily, a large patient population
presenting with diabetic nephropathy, and the a priori de-
fined outcome measures over the mean follow-up period.
Are the design of the RENAAL study and the analysis of
data in compliance with the requirements of evidence-
based medicine? The perusal of the report [1] raises con-
cern, regarding to both the patient population as well as
the outcome measures.
Patient population
Randomization
The losartan group and the placebo group were not com-
pletely equal, and this might influence the results: in the
placebo group there were 10 more patients with angina
than in the losartan group, 19 more with myocardial inf-
arction, and 37 more with lipid disorders. Triglyceride lev-
el was also higher in the placebo group. Albeit the
differences were not significant when separately consid-
ered, the cumulative influence of these clinical features on
patients' outcome cannot be excluded. For instance, it can
be presumed that a history of myocardial infarction is of
overwhelming importance for the rate of hospitalization
due to heart failure. This point is of special relevance in
view of the higher rate of first hospitalization due to heart
failure in the placebo group as compared with losartan
group. Thus, a conceivable explanation for this outcome
is that patients in the placebo group were more prone to
suffer from heart failure than their counterparts on losar-
tan treatment.
Glucose metabolism
It is disappointing that glycosylated hemoglobin values
are reported only at baseline. Moreover, data on plasma
glucose levels are not reported at all. Such information
should not be disregarded in a study dealing with diabetic
patients. The relationship between hyperglycemia and
mortality is roughly linear, including asymptomatic pa-
tients with impaired fasting glucose [3], and tight glucose
control reduces the risk of micro vascular complications
such as renal disease [4]. Thus, information on glucose
metabolism characteristics is crucial, since glycosylated
hemoglobin or glucose levels per se could be a factor of
strong repercussion on patients' outcome.
Antihyperglycemic drugs
The significance of hypertension in diabetic patients con-
trolled on diet only versus those pharmacologically treat-
e d  i s  d i f f e r e n t  [ 5 ] .  I n  t h i s  c o n t e x t ,  d a t a  o n
antihyperglycemic medication is essential. Moreover, sul-
fonylureas – which constitute a mainstay therapy in the
diabetic patient – may have undesirable influences on car-
diac performance, especially in the presence of a previous-
ly damaged myocardium [6]. Moreover, the widely used
combined treatment of glyburide (a sulfonylurea known
also as glibenclamide in European countries) and met-
formin is associated with increased mortality, in both pa-
tients with ischemic heart disease [7] and in the general
population [8]. It would be advisable to collect data on
antihyperglycemic therapy for both the losartan and pla-
cebo groups and to include these data in a multivariate
analysis, since it seems almost obvious that these thera-
peutic agents could affect primary and secondary end
points. Such data are missing in the final report of the RE-
NAAL study [1].
Outcome measures
Composite endpoint
The RENAAL study employed a composite end point con-
sisting of a doubling of serum creatinine, end-stage renal
disease, or death in order to assess the efficacy of losartan.
The employment of combined end points that use a com-
bination of nonfatal events with death has been criticized
[2,9], since they may lead to the camouflage of a negative
outcome or result in a dilution of the effects of the thera-
peutic agent on mortality [10]. The methodological draw-
backs of employing a composite end point are clearly
perceived in the study: while substantial risk reductions
were reported for the losartan group with regard to dou-
bling of serum creatinine and end-stage renal disease, the
death rate was relatively higher. It is possible that this
could reflect a somewhat longer follow-up period in this
group, as the authors state. In any case, the results evident-
ly show no benefit in mortality rates in the losartan group.
Serum creatinine
The doubling of serum creatinine in the RENAAL study
represents a surrogate end point. This is defined as a
'marker' or laboratory measurement that is used in thera-
peutic trials as a substitute for a meaningful end point that
is a direct measure of how a patient feels, functions, or sur-
vives and is expected to predict the effect of the therapy
[11]. Surrogates are thought to reflect the activity of the
underlying process that leads to an adverse outcome, since
both surrogate and real end points are expected to move
in the same direction [12]. In the RENAAL study the dou-
bling of creatinine was defined as the first serum creati-Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/2
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nine value that was twice the baseline value, confirmed by
a similar second value at least four weeks after the initial
doubling. Does creatinine represent a reliable surrogate?
The response seems to be negative, since creatinine can in-
crease acutely from dietary ingestion of cooked meat and
can be blocked by some commonly used medications like
cimetidine and trimethoprim [13].
Hospitalizations
Hospitalization is a commonly used outcome reflecting
morbidity. Regarding secondary outcomes, no significant
differences were documented between the losartan group
and the placebo group in the rates of most cardiovascular
end points, excepting first hospitalization due to heart
failure. In this aspect, the risk was reduced by 32% in favor
of the losartan group. The problem with this outcome is
that its meaningfulness is limited when only data on first
hospitalization are reported whilst information on total
specific-cause hospitalizations is disregarded, thus poten-
tially masking further unfavorable events [9].
Final comment
Recent reports have suggested that angiotensin receptor
blockers [14] similarly to angiotensin-converting enzyme
inhibitors [15], provide renoprotective effects in diabetic
patients. In this context, based on its mechanism of ac-
tion, losartan may share these favorable properties. Recent
data from the LIFE (Losartan Intervention For Endpoint
reduction in hypertension) trial [16] indicate that losartan
was significantly more effective than the beta blocker at-
enolol in reducing cardiovascular morbidity and death in
hypertensive patients with left ventricular hypertrophy .
Indeed, patients taking losartan were less likely to develop
type 2 diabetes during the study, and a separate analysis of
diabetic patients showed a reduced risk of cardiovascular
mortality. However, due to the methodological flaws and
the incomplete data in the RENAAL study [1], the ques-
tion of the effectiveness and safety of this drug in the spe-
cific setting of patients with diabetic nephropathy remains
yet unanswered. Further elucidation of the issues that we
discuss may contribute to clarify the uncertainties.
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